Tagged with Innovation,

basic research The Thailand Center of Excellence for Life Sciences (TCELS) CEO shares his ambitions to make Thailand a place for innovative business practices, the organization’s role in promoting and supporting research and the unique role TCELS plays in creating a regulatory frameworks for the life sciences industry. What special experiences led…

Otsuka Thai Otsuka’s president explains the Otsuka Group’s commitment to Thailand, the tremendous potential they see in the market in light of the opening up of the ASEAN Economic Community and his personal ambitions to ensure the company remains on a successful path. What is the importance of the Otsuka Group’s…

innovation Nilsa Martinez, general manager of Pace Analytical Puerto Rico, outlines the affiliate’s services in microbiology and chemistry analysis as a critical service provider to the local life sciences industry. You have been General Manager of Pace Analytical since 2010. What initially drove you to this company and what were the…

hospitals The managing director at Adcock Ingram Critical Care reveals the company’s unique business model. As a long-established division within Adcock Ingram, Critical Care operates with relative independence. What is the relationship between Critical Care and the group? We had historical group strategy focused on a centralized business model, with one of…

innovation The chairman for the National Innovation Agency (NIA), Mr. Somchet Thinapong, shares his personal ambitions to bring innovation to the forefront of Thailand’s agenda, why innovation is vital to ensuring the success of the nation and where he hopes to see Thailand’s innovation strategy in the coming years. What experiences…

Janssen The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching a product on the Romanian market. He also speaks extensively about the state of the local medical device market and its likely future potential. Can…

GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…

Daiichi Sankyo The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great place to work’ awards.  In 2012, you had made it a goal to develop the Turkish affiliate into a regional…

Daiichi Sankyo Daiichi Sankyo Thailand’s managing director explains the Thai subsidiary’s success under his leadership, Thailand’s untapped potential as a regional economic center in Southeast Asia and his company’s role in providing high quality products for consumers in Thailand.   What have been your greatest challenges and achievements as Managing Director? During my tenure in…

Astellas The country manager of a Japanese speciality pharma firm sheds light on his preparations for an eventual opening up of the national reimbursement list and speaks out about how Romania is fast becoming an outlier for organ transplants. How do you evaluate your tenure as country manager of Astellas Romania…

BMS The country manager of a leading specialty care bio-business reveals how the economic and geo-social fundamentals in Romania are highly attractive from an innovative pharmaceutical producer standpoint. He speaks about how to navigate the complex regulatory landscape and the potential opportunity for preventative care to make the nation’s healthcare system…

Pfizer The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is to devise different sustainable business models that allow for more affordable medicines, and how Pfizer must crack the emerging market…